MX2019014665A - Nuevos derivados de azaindolina sustituida como inhibidores de nik. - Google Patents

Nuevos derivados de azaindolina sustituida como inhibidores de nik.

Info

Publication number
MX2019014665A
MX2019014665A MX2019014665A MX2019014665A MX2019014665A MX 2019014665 A MX2019014665 A MX 2019014665A MX 2019014665 A MX2019014665 A MX 2019014665A MX 2019014665 A MX2019014665 A MX 2019014665A MX 2019014665 A MX2019014665 A MX 2019014665A
Authority
MX
Mexico
Prior art keywords
disorders
new substituted
nik
inhibitors
nik inhibitors
Prior art date
Application number
MX2019014665A
Other languages
English (en)
Inventor
Virginie Sophie Poncelet
Lieven Meerpoel
Olivier Alexis Georges Querolle
Edgar Jacoby
Calum Macleod
Janusz Jozef Kulagowski
Samuel Edward Mann
George Hynd
Ian Stansfield
Gerhard Max Gross
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019014665A publication Critical patent/MX2019014665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero y en particular a inhibidores de la cinasa inductora de NF-?B (NIK -también conocida como MAP3K14) útiles para tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos y trastornos autoinmunitarios. La invención también se refiere a composiciones farmacéuticas que comprenden tales compuestos, y al uso de tales compuestos o composiciones farmacéuticas para la prevención o el tratamiento de enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos que incluyen obesidad y diabetes, y trastornos autoinmunitarios.
MX2019014665A 2017-07-06 2018-07-04 Nuevos derivados de azaindolina sustituida como inhibidores de nik. MX2019014665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180010 2017-07-06
PCT/EP2018/068048 WO2019008011A1 (en) 2017-07-06 2018-07-04 NOVEL SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS

Publications (1)

Publication Number Publication Date
MX2019014665A true MX2019014665A (es) 2020-07-29

Family

ID=59295074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014665A MX2019014665A (es) 2017-07-06 2018-07-04 Nuevos derivados de azaindolina sustituida como inhibidores de nik.

Country Status (12)

Country Link
US (1) US11236084B2 (es)
EP (1) EP3649127B1 (es)
JP (1) JP7213193B2 (es)
KR (1) KR102662373B1 (es)
CN (1) CN110831940B (es)
AU (1) AU2018297592B2 (es)
BR (1) BR112020000010A2 (es)
CA (1) CA3066166A1 (es)
ES (1) ES2901829T3 (es)
IL (1) IL271808B (es)
MX (1) MX2019014665A (es)
WO (1) WO2019008011A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38721A (es) 2019-05-31 2020-11-30 Janssen Pharmaceutica Nv INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
CA3174992A1 (en) * 2020-03-02 2021-09-10 Sironax Ltd. Ferroptosis inhibitors - diarylamine para-acetamides
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4160401B2 (ja) 2001-03-29 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ−ｊｕｎｎ末端キナーゼ（ｊｎｋ）および他のタンパク質キナーゼのインヒビター
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
JP6333826B2 (ja) * 2012-10-11 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アザインドリン
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN106928216A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途

Also Published As

Publication number Publication date
KR20200024852A (ko) 2020-03-09
RU2020105249A3 (es) 2021-09-30
RU2020105249A (ru) 2021-08-06
BR112020000010A2 (pt) 2020-07-21
EP3649127B1 (en) 2021-09-08
US20210188840A1 (en) 2021-06-24
KR102662373B1 (ko) 2024-04-29
JP7213193B2 (ja) 2023-01-26
IL271808B (en) 2022-08-01
US11236084B2 (en) 2022-02-01
WO2019008011A1 (en) 2019-01-10
IL271808A (en) 2020-02-27
EP3649127A1 (en) 2020-05-13
CA3066166A1 (en) 2019-01-10
CN110831940B (zh) 2023-06-20
AU2018297592A1 (en) 2019-12-05
ES2901829T3 (es) 2022-03-23
JP2020525471A (ja) 2020-08-27
CN110831940A (zh) 2020-02-21
AU2018297592B2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX2017005285A (es) Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX2016003861A (es) Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX365739B (es) Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX369159B (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
GEP20217316B (en) Aromatic sulfonamide derivatives
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
PH12016502353A1 (en) Pharmaceutical composition
CR20220207A (es) Compuestos terapéuticos y métodos de uso
TW201613577A (en) Pharmaceutical combinations
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
GEP20227442B (en) Boron containing pde4 inhibitors
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2021015898A (es) Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d.
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов